Project

Registered Clinical Trials Investigating 3,4-Methylenedioxymethamphetamine (MDMA) For Psychiatric Disorders

OSFFeb 18, 2022

Abstract

This review incorporated components from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P; Shamseer et al., 2015) with methods for examining registered clinical trials of 3,4-Methylenedioxymethamphetamine (MDMA) for psychiatric disorders.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

MDMADepression

Keywords

3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine” OR “MDMA”] AND [“major depressive disorder” OR “suicide” OR “bipolar disorderobsessiveBipolarMajor Depressive Disorder

View project

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023

ArticleMDMA

Prevalence and Psychiatric Correlates of Illicit Substance Use in UK Undergraduate Students.

Foster H, Stevenson J, Akram U